Targeting the PI3K/mTOR Pathway in Murine Endocrine Cell Lines-Reference-Cited by-同舟云学术

Targeting the PI3K/mTOR Pathway in Murine Endocrine Cell Lines

Published:2011-01 Issue:1 Volume:178 Page:336-344
ISSN:0002-9440
Container-title:The American Journal of Pathology
language:en
Short-container-title:The American Journal of Pathology

Author:

Couderc Christophe,Poncet Gilles,Villaume Karine,Blanc Martine,Gadot Nicolas,Walter Thomas,Lepinasse Florian,Hervieu Valérie,Cordier-Bussat Martine,Scoazec Jean-Yves,Roche Colette

Funder

Comité de la Drôme de la Ligue contre le Cancer

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference27 articles.

1. Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives;Hopfner;World J Gastroenterol,2008

2. Defining the role of mTOR in cancer;Guertin;Cancer Cell,2007

3. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study;Yao;J Clin Oncol,2008

4. Temsirolimus, an inhibitor of mammalian target of rapamycin;Rini;Clin Cancer Res,2008

5. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line;Grozinsky-Glasberg;Neuroendocrinology,2008

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications;Frontiers in Oncology;2022-08-17

2. Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study;European Journal of Cancer;2019-12

3. The expression of TTF1, CDX2 and ISL1 in 74 poorly differentiated neuroendocrine carcinomas;Annals of Diagnostic Pathology;2018-12

4. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma;Biomedicine & Pharmacotherapy;2018-10

5. Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets;Endocrine Connections;2018-01